SATTVASUKU.BO · BSE
SATTVA SUKUN LIFECARE LIMITED
₹1.18
-0.84% (-₹0.01)
Prev. close
₹1.19
Volume
7
As of
BSE · may be slightly delayed · 16:00 IST
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About SATTVA SUKUN LIFECARE LIMITED
Tavexia Lifecare Limited manufactures and trades in burners in India. The company engages in buying, selling, exporting, importing, processing, converting, laminating re process, and dealing in all models, shapes, sizes, capacities, and varieties of burner and other products. Its product portfolio includes kapoor and ceramic kapoor dani; aroma, aroma oil, aroma with timer, navkar mantra, and night lamp burner; decorative and night lamps; home and office decoration lighting products, flowerpots with lighting, and lighting flower vase; vaporizers and camphor sticks; and rolly polly. The company is also involved in the distribution, retailing, and wholesaling of products. It sells its products through outlets and online selling platforms portals, such as India Mart, Amazon, Flipkart, Snapdeal, etc. The company was formerly known as Sattva Sukun Lifecare Limited and changed its name to Tavexia Lifecare Limited in August 2026. Tavexia Lifecare Limited was incorporated in 1980 and is based in Mumbai, India.
Details
Key stats
Market cap
₹33.76 Cr
EPS (TTM)
₹-0.03
Beta (1Y · daily vs NIFTY 50)
0.29
Beta (5Y · monthly vs NIFTY 50)
0.30
Shares float
10.41 Cr
EPS · quarter ended Jun 2026
₹-0.00
Financial Performance
01 · Financials
The first plotted growth figure is computed against Mar 2022 revenue as filed with BSE; the two sources' revenue definitions differ by 0.0% on Mar 2023. FY23 growth needs FY22 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| ₹1.54 Cr | ₹2.21 Cr | ₹3.55 Cr | ₹5.26 Cr | ₹32.25 Cr | |
| EBITDA | ₹11.00 L | ₹1.02 Cr | ₹1.93 Cr | ₹3.66 Cr | ₹75.68 L |
| ₹1.90 L | ₹55.35 L | ₹1.19 Cr | ₹2.49 Cr | ₹21.17 L | |
| Diluted EPS | — | ₹0.04 | ₹0.05 | ₹0.11 | ₹0.01 |
Depreciation & amortisation, Pretax income, Tax provision, Interest expense, Diluted EPS have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| — | ₹16.36 Cr | ₹23.28 Cr | ₹26.58 Cr | ₹111.35 Cr | |
| — | ₹23.72 L | ₹16.66 L | ₹51.83 L | ₹3.51 Cr | |
| Stockholders' equity | — | ₹15.49 Cr | ₹22.20 Cr | ₹23.96 Cr | ₹43.23 Cr |
Total assets, Current assets, Trade receivables, Cash & equivalents, Non-current assets, Fixed assets, Total debt, Long-term debt, Current (short-term) debt, Others, Stockholders' equity have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| — | ₹-1.47 Cr | ₹-2.77 Cr | ₹10.90 L | ₹-14.34 Cr | |
| Investing cash flow | — | ₹-9.68 Cr | ₹-2.77 Cr | ₹-48.19 L | ₹-3.61 Cr |
| Financing cash flow | — | ₹11.16 Cr | ₹5.51 Cr | ₹37.10 L | ₹19.32 Cr |
| Capital expenditure | — | ₹-1.58 Cr | ₹-21,000 | ₹-48.19 L | ₹-3.19 Cr |
| End cash position | — | ₹7.06 L | ₹4.01 L | ₹3.82 L | ₹1.41 Cr |
Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Capital expenditure, End cash position have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
Documents
Annual reports
Show all 15
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Tavexia Lifecare proposes acquisition of 60% stake in Meyonex Pharmaceuticals
Tavexia Lifecare Limited proposes to acquire up to a 60% stake in Meyonex Pharmaceuticals Limited to expand into pharmaceutical manufacturing. This move aligns with Tavexia's strategic shift towards the pharmaceutical, chemicals, and lifecare sectors. The acquisition is subject to due diligence, valuation, and negotiations.
Tavexia Lifecare Advances Strategic Growth Roadmap with Proposed Acquisition of Meyonex Pharmaceuticals
5 Dariya News · 9 days ago